Cargando…
Reduction in Endometrioma Size with Three Months of Aromatase Inhibition and Progestin Add-Back
The purpose of this study was to assess the impact of 3 months of aromatase inhibition together with progestin add-back on ovarian endometrioma size. This prospective cohort study was performed at University Medical Center (UC San Diego). Women trying to conceive were excluded. After informed consen...
Autores principales: | Agarwal, Sanjay K., Foster, Warren G. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4515259/ https://www.ncbi.nlm.nih.gov/pubmed/26247030 http://dx.doi.org/10.1155/2015/878517 |
Ejemplares similares
-
Progestin-Primed Ovarian Stimulation Protocol for Patients With Endometrioma
por: Yang, Ai-Min, et al.
Publicado: (2022) -
Progestin and aromatase inhibitor therapy in recurrent, estrogen/progestin receptor positive uterine carcinosarcoma: A case report
por: Liang, Angela L., et al.
Publicado: (2021) -
Treatment of Endometriosis with the GnRHa Deslorelin and Add-Back Estradiol and Supplementary Testosterone
por: Agarwal, Sanjay K., et al.
Publicado: (2015) -
Efficacy of N-Acetylcysteine on Endometriosis-Related Pain, Size Reduction of Ovarian Endometriomas, and Fertility Outcomes
por: Anastasi, Emanuela, et al.
Publicado: (2023) -
Prospective, randomized, double-blind, placebo-controlled phase IIa clinical trial on the effects of an estrogen-progestin combination as add-on to inpatient psychotherapy in adult female patients suffering from anorexia nervosa
por: Paslakis, Georgios, et al.
Publicado: (2018)